Author Archives: cardioscripts

Dr. Barbara Wiggins joins the CardioScripts team to talk about the ISCHEMIA trial. 0:00-0:40: Intro0:41-1:22: Introduction of Dr. Barbara Wiggins1:23-5:26: Introduction of ISCHEMIA5:27-6:37: Barbara’s Overall Thoughts6:38-7:33: What does the ISCHEMIA trial add to COURAGE?7:34-8:27: Patient Baseline Medication Regimens8:28-10:42: ISCHEMIA Questions10:43-11:51: ISCHEMIA Implications for Pharmacy Practice11:52-14:03: Barbara’s Final Thoughts14:04-14:48: Closing References: ISCHEMIA Trial: The ISCHEMIA TrialContinue reading “Crushing ISCHEMIA with Dr. Barbara Wiggins”

Dr. Ben Van Tassell discusses sacubatril-valsartan and the PIONEER-HF trial. 0:00-0:40: Intro0:41-1:14: Introduction of Dr. Ben Van Tassell1:15-4:00: Introduction of PIONEER-HF4:01-5:22: Ben’s Initial Thoughts5:23-6:40: Sacubatril-valsartan right out of the gate?6:41-7:50: Thoughts on open-label expansion trial7:51-11:12: Role of NT-proBNP as a surrogate endpoint11:13-14:17: Cost considerations with sacubitril-valsartan14:18-15:33: Patient follow-up in a real-world setting15:34-16:13: Closing References: PIONEER-HF:Continue reading “PIONEERing HF Care with Dr. Van Tassell”

0:00-0:40: Intro0:41-1:22: Introduction of Dr. Kathleen Faulkenberg1:23-5:45: Overview of TOPCAT5:46-8:28: Kathleen’s Overall Thoughts 8:29-10:11: TOPCAT Controversy10:12-11:15: Spironolactone Metabolite Differences Between Regions11:16-11:59: More Questions Around TOPCAT12:00-12:51: What do we do with results from TOPCAT?12:52-15:19: Final Thoughts15:20-16:01: Closing References: TOPCAT: Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014;370:1383-92.Continue reading “Spironolactone: TOPCAT or underdog?”

Check out this episode as Dr. Dave Dixon talks about REDUCE-IT and REDUCE-IT USA.  0:00-0:41: Intro0:42-1:26: Introduction of Dr. Dave Dixon1:27-5:10: Introduction of REDUCE-IT and REDUCE-IT USA5:11-6:30: Dave’s Initial Thoughts6:31-8:21: Why not OTC fish oil or omega-3 fatty acid prescriptions?8:22-9:54: Were these patients well managed at baseline?9:55-11:15: Who should we avoid icosapent ethyl in?11:16-12:19: LabelingContinue reading “Plenty of fish [oil] in the sea, have we REDUCEd-IT to one?”

In this episode, Dr. Zac Noel helps us navigate through the ENTRUST-AF PCI trial as well as dual vs. triple antithrombotic therapy. 0:00-0:40: Intro0:41-1:42: Introduction of Dr. Zachery Noel1:43-4:35: ENTRUST-AF PCI Overview4:36-5:46: Zac’s Overall Thoughts5:47-6:33: Dual antithrombotic therapy for everyone?6:34-7:38: Patient population in ENTRUST-AF PCI7:39-9:03: Other P2Y12 inhibitors9:04-10:13: Ischemic outcomes10:14-11:18: Who should receive dual antithromboticContinue reading “In Zac Noel we ENTRUST: Double or Nothing?”

Prepare to dive into the TWILIGHT trial with Dr. Craig Beavers. 0:00-0:22: Intro0:23-1:01: Introduction of Dr. Craig Beavers1:02-3:32: TWILIGHT Overview3:33-6:31: Craig’s Overall Thoughts6:32-8:39: Excluded Patients8:40-10:17: Ticagrelor Monotherapy and Ischemic Outcomes10:18-12:52: TWILIGHT and GLOBAL LEADERS12:53-14:24: Final Thoughts14:25-15:22: Closing/Craig’s Upcoming Podcast References: TWILIGHT: Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High-RiskContinue reading “Entering the TWILIGHT Zone”

In the second of two episodes, Drs. Rob DiDomenico and Kerry Pickworth provide their expertise about PGY2 Cardiology residency training. 0:00-0:40: Intro0:41-2:46: Physical exam in the cardiology setting2:47-6:17: Importance of interpreting diagnostic tests6:18-9:02: Keeping up with literature9:03-11:29: Importance of self-reflection11:30-15:00: Final thoughts/Free time (?) References: Ng TMH, DiDomenico RJ, Ripley TL, et al. An opinionContinue reading “Been there, done that: Expert advice from parting RPDs (Part 2)”

In the first of two episodes, Drs. Rob DiDomenico and Kerry Pickworth provide their expertise about Midyear for prospective PGY2 Cardiology residency candidates.  0:00-0:40: Intro0:41-2:22: Introduction of Drs. Rob DiDomenico and Kerry Pickworth2:23-3:17: Overview of PGY2 Cardiology Pharmacy Resident Training Opinion Paper3:18-4:56: Rob and Kerry’s Overall Thoughts4:57-9:08: Midyear Advice/What are you looking for in aContinue reading “Been there, done that: Expert advice from parting RPDs (Part 1)”

0:00-0:46: Intro0:47-1:20: Introduction of Dr. Ted Berei1:21-2:57: DAPA-HF Overview2:58-6:12: Ted’s Overall Thoughts6:13-7:24: DAPA-HF Patient Population7:25-9:15: Sacubitril/valsartan or Dapagliflozin First?9:16-10:47: Considerations Prior to Starting SGLT2 Inhibitors10:48-12:19: SGLT2 Inhibitors and Cost12:20-14:43: Final Thoughts14:44-15:42: Closing/Introduction to Finn References:  DAPA-HF: McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl JContinue reading “Episode 3: How sweet it is to be an SGLT2 Inhibitor”

In this episode, we review the ISAR-REACT 5 trial and hear Dr. Steve Dunn’s thoughts about how this trial fits into P2Y12 management in patients with acute coronary syndromes.  Episode:0:00-0:40: Intro0:41-1:23: Introduction of Dr. Steve Dunn1:24-3:42: ISAR-REACT 5 Overview3:43-6:28: Steve’s Overall Thoughts6:29-7:59: Context of ISAR-REACT 58:00-9:34: Study Funding9:35-11:25: Study Discontinuation Rate11:26-12:50: Secondary Safety Outcomes12:51-15:51: FinalContinue reading “Episode 2: REACT(5)ion from Steve Dunn”